MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure - Evaluation of Morphologic and Functional Changes in a Randomized Setting
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Mitral Valve Insufficiency
- Sponsor
- Heart Center Leipzig - University Hospital
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Change in Exercise tolerance: 6 minute walking test
- Last Updated
- 4 years ago
Overview
Brief Summary
Aim of this prospective trial is to assess the hemodynamic effects of a MitraClip procedure caused iatrogenic arterial septal defect (iASD) and the functional changes after interventional iASD closure in a randomized setting.
Detailed Description
Transcatheter mitral valve repair with the MitraClip system is a therapeutic alternative to surgery in selected high-risk patients. Clip placement requires interatrial transseptal puncture and meticulous manipulation of the steerable sheath. There is evidence that the persistence of a relevant iASD after MitraClip is associated with worse clinical outcomes and increased mortality. The purpose of this study is to investigate, if the interventional closure of an persistant hemodynamic relevant iASD 30 days after MitraClip implantation, has favorable effects on clinical outcome. Eligible patients, after obtaining written informed consent, are 1:1 randomized either in group A (interventional occlusion of iASD) or group B (best supportive care).
Investigators
Philipp Lurz
Clinical Investigator, Professor, Managing Senior Physician
Heart Center Leipzig - University Hospital
Eligibility Criteria
Inclusion Criteria
- •Informed consent
- •Previous MitraClip implantation
- •Persistent relevant iASD 30 days after MitraClip intervention
Exclusion Criteria
- •Unsuccessful MitraClip implantation
- •No relevant iASD 30 days after MitraClip intervention
- •Unstable angina in the previous 4 weeks
- •Valvular heart disease (aortic, tricuspid or pulmonary valve) planed for surgery or interventional therapy
- •Constrictive pericarditis / restrictive cardiomyopathies
- •Pericardial effusion planed for surgery or interventional therapy
- •Coagulation disorders
- •Malignant disease with a life expectance \< 12 months
- •Pregnancy
- •Participation in another study
Outcomes
Primary Outcomes
Change in Exercise tolerance: 6 minute walking test
Time Frame: baseline, 3 and 6 months
Secondary Outcomes
- Changes in Echocardiography: bi ventricular function (2D and 3D)(baseline, 3 and 6 months)
- Changes in Echocardiography: strain using speckle tracking(baseline, 3 and 6 months)
- Changes in Cardiac MRI: flow measurements in main pulmonary artery and aorta(baseline and 6 months)
- Evaluation of hospitalisation rate(baseline, 3, 6 and 12 months)
- Changes in quality of life in "Minnesota Living with Heart Failure" questionnaire(baseline and 6 months)
- Combined endpoint (hospitalisation and mortality)(baseline, 3, 6 and 12 months)
- Change in New York Heart Association Functional Classification assessment(baseline, 3 and 6 months)
- Changes in Echocardiography: assessment of left atrium (2D and 3D)(baseline, 3 and 6 months)
- Changes in Echocardiography: assessment of heart valves(baseline, 3 and 6 months)
- Changes in Echocardiography: evaluation of iatrogenic ASD (2D and 3D)(baseline, 3 and 6 months)
- Heart insufficiency bio markers(baseline and 6 months)
- Evaluation of mortality(baseline, 3, 6 and 12 months)
- Changes in Cardiac MRI: left ventricular circumferential strain(baseline and 6 months)
- Changes in Cardiac MRI: bi ventricular function(baseline and 6 months)
- Changes in Cardiac MRI: left ventricular longitudinal strain(baseline and 6 months)
- Changes in quality of life in "Short Form - 36" questionnaire(baseline and 6 months)